AstraZeneca PLC (NASDAQ/LSE: AZN) is widely viewed by institutional analysts as a solid long-term holding or buy candidate, supported by a massive global oncology pipeline, robust vaccine and specialty care portfolios, and consistent revenue generation. Analysts frequently emphasize its diversified geographic footprint and heavy R&D reinvestment as key drivers, though individual portfolio suitability depends on specific growth versus income goals.